189 related articles for article (PubMed ID: 29201193)
21. Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity.
Casanova-Ferrer F; Gallego JJ; Fiorillo A; Urios A; Ríos MP; León JL; Ballester MP; Escudero-García D; Kosenko E; Belloch V; Montoliu C
J Transl Med; 2024 Jan; 22(1):49. PubMed ID: 38217008
[TBL] [Abstract][Full Text] [Related]
22. Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal.
Pawar VB; Surude RG; Sonthalia N; Zanwar V; Jain S; Contractor Q; Rathi PM
J Clin Transl Hepatol; 2019 Dec; 7(4):304-312. PubMed ID: 31915599
[No Abstract] [Full Text] [Related]
23. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis.
Liu Q; Duan ZP; Ha DK; Bengmark S; Kurtovic J; Riordan SM
Hepatology; 2004 May; 39(5):1441-9. PubMed ID: 15122774
[TBL] [Abstract][Full Text] [Related]
24. Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy.
Mangas-Losada A; García-García R; Leone P; Ballester MP; Cabrera-Pastor A; Urios A; Gallego JJ; Martínez-Pretel JJ; Giménez-Garzó C; Revert F; Escudero-García D; Tosca J; Ríos MP; Montón C; Durbán L; Aparicio L; Montoliu C; Felipo V
J Transl Med; 2019 Aug; 17(1):293. PubMed ID: 31462286
[TBL] [Abstract][Full Text] [Related]
25. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition.
Kang DJ; Kakiyama G; Betrapally NS; Herzog J; Nittono H; Hylemon PB; Zhou H; Carroll I; Yang J; Gillevet PM; Jiao C; Takei H; Pandak WM; Iida T; Heuman DM; Fan S; Fiehn O; Kurosawa T; Sikaroodi M; Sartor RB; Bajaj JS
Clin Transl Gastroenterol; 2016 Aug; 7(8):e187. PubMed ID: 27560928
[TBL] [Abstract][Full Text] [Related]
26. Rifaximin, Microbiota Biology, and Hepatic Encephalopathy.
Peleman C; Camilleri M
Clin Transl Gastroenterol; 2016 Oct; 7(10):e195. PubMed ID: 27711069
[TBL] [Abstract][Full Text] [Related]
27. Characterization of intestinal microbiota and serum metabolites in patients with mild hepatic encephalopathy.
Lin Y; Yan G; Feng F; Wang M; Long F
Open Life Sci; 2022; 17(1):139-154. PubMed ID: 35350446
[TBL] [Abstract][Full Text] [Related]
28. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial.
Madsen BS; Trebicka J; Thiele M; Israelsen M; Arumugan M; Havelund T; Krag A
Trials; 2018 Feb; 19(1):143. PubMed ID: 29482588
[TBL] [Abstract][Full Text] [Related]
29. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.
Sharma P; Sharma BC; Puri V; Sarin SK
Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):506-11. PubMed ID: 18467909
[TBL] [Abstract][Full Text] [Related]
30. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome.
Yu X; Jin Y; Zhou W; Xiao T; Wu Z; Su J; Gao H; Shen P; Zheng B; Luo Q; Li L; Xiao Y
Front Cell Infect Microbiol; 2021; 11():761192. PubMed ID: 35118004
[TBL] [Abstract][Full Text] [Related]
31. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy.
Ziada DH; Soliman HH; El Yamany SA; Hamisa MF; Hasan AM
Arab J Gastroenterol; 2013 Sep; 14(3):116-22. PubMed ID: 24206740
[TBL] [Abstract][Full Text] [Related]
32. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
33. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Mittal VV; Sharma BC; Sharma P; Sarin SK
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
[TBL] [Abstract][Full Text] [Related]
34. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
36. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.
Gupta A; Dhiman RK; Kumari S; Rana S; Agarwal R; Duseja A; Chawla Y
J Hepatol; 2010 Nov; 53(5):849-55. PubMed ID: 20675008
[TBL] [Abstract][Full Text] [Related]
37. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis.
Cao Q; Yu CB; Yang SG; Cao HC; Chen P; Deng M; Li LJ
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):9-16. PubMed ID: 29428113
[TBL] [Abstract][Full Text] [Related]
38. Alcohol, liver disease and the gut microbiota.
Bajaj JS
Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
[TBL] [Abstract][Full Text] [Related]
39. Reversal of Low-Grade Cerebral Edema After Lactulose/Rifaximin Therapy in Patients with Cirrhosis and Minimal Hepatic Encephalopathy.
Rai R; Ahuja CK; Agrawal S; Kalra N; Duseja A; Khandelwal N; Chawla Y; Dhiman RK
Clin Transl Gastroenterol; 2015 Sep; 6(9):e111. PubMed ID: 26378384
[TBL] [Abstract][Full Text] [Related]
40. Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome.
Zhuang X; Tian Z; Li L; Zeng Z; Chen M; Xiong L
Front Microbiol; 2018; 9():1600. PubMed ID: 30090090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
